Difficulty: Medium
Average Score: 83%
Practice
Blood level of which clotting factor declines most rapidly after the initiation of warfarin therapy
Correct answer
A
Rationale
The correct answer is A) Factor VII. When considering the effects of warfarin therapy on clotting factors, Factor VII stands out as the clotting factor whose blood level declines most rapidly after the initiation of treatment. Factor VII has the shortest half-life among vitamin K-dependent clotting factors, around 4-6 hours, making it more susceptible to the anticoagulant effects of warfarin which inhibits vitamin K-dependent clotting factor synthesis.
Factor IX, Factor X, and Prothrombin (Factor II) have longer half-lives compared to Factor VII. Factor IX has a half-life of around 24 hours, Factor X has a half-life of about 40-45 hours, and Prothrombin has a half-life of approximately 60-72 hours. Therefore, these factors are not as rapidly affected by warfarin therapy as Factor VII.
In an educational context, understanding the pharmacological effects of warfarin on clotting factors is crucial for healthcare professionals involved in managing patients on anticoagulant therapy. This knowledge helps in monitoring and adjusting treatment regimens to maintain a balance between preventing thrombosis and avoiding bleeding complications. It also highlights the importance of individualizing therapy based on the patient's response to treatment and monitoring parameters such as international normalized ratio (INR) to ensure therapeutic efficacy and safety.
Factor IX, Factor X, and Prothrombin (Factor II) have longer half-lives compared to Factor VII. Factor IX has a half-life of around 24 hours, Factor X has a half-life of about 40-45 hours, and Prothrombin has a half-life of approximately 60-72 hours. Therefore, these factors are not as rapidly affected by warfarin therapy as Factor VII.
In an educational context, understanding the pharmacological effects of warfarin on clotting factors is crucial for healthcare professionals involved in managing patients on anticoagulant therapy. This knowledge helps in monitoring and adjusting treatment regimens to maintain a balance between preventing thrombosis and avoiding bleeding complications. It also highlights the importance of individualizing therapy based on the patient's response to treatment and monitoring parameters such as international normalized ratio (INR) to ensure therapeutic efficacy and safety.